HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cisplatin and mild hyperthermia in radiosensitization to low dose rate irradiation in human ovarian carcinoma cells.

Abstract
Two human ovarian carcinoma cell lines, one parental and the other a cisplatin resistant derivative cell line, were evaluated for the efficacy of combined treatments of mild hyperthermia, cisplatin and low dose rate irradiation (LDRI). The data showed that cisplatin (1 or 3 micrograms/ml for 1 hour) combined with mild hyperthermia (40 degrees C for 1 hour) was effective for radiosensitization to LDRI in the parental cell line whether given before or after irradiation. In the cisplatin resistant variant, however, these treatments had little to no effect on LDRI response. Thus these data show that these treatments could be clinically effective if there is no cisplatin resistance. Our previous study showed that concomitant treatments could be effective in both parental and cisplatin resistant cell line (1).
AuthorsG P Raaphorst, J Miao, C E Ng
JournalAnticancer research (Anticancer Res) 1997 Sep-Oct Vol. 17 Issue 5A Pg. 3469-72 ISSN: 0250-7005 [Print] Greece
PMID9413189 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cisplatin
Topics
  • Cell Survival (drug effects, radiation effects)
  • Cisplatin (administration & dosage)
  • Combined Modality Therapy
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Hyperthermia, Induced
  • Ovarian Neoplasms (drug therapy, radiotherapy)
  • Radiation, Ionizing
  • Time Factors
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: